33 results about "Levodopa" patented technology

The present invention generally provides methods and compositions for the treatment of Parkinson's disease and depression and / or anxiety. The invention relates to recombinant microorganisms, particularly gut-colonizing probiotics, modified to produce L-DOPA.

The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.

The application relates to the detection field and provides a method for detecting levodopa, which comprises the following steps: contacting a to-be-detected sample with a sensor to generate a detectable signal; the sensor comprises a working electrode, and the surface of the working electrode is loaded with UiO-66 material; a detection result of the to-be-detected sample is obtained based on the detectable signal; the Ui-O66 material is prepared by reacting terephthalic acid or a derivative thereof and a soluble zirconium salt for a predetermined time, and the predetermined time is determined based on known components of the to-be-detected sample. The method selects the reaction time of the UiO-66 material to regulate the proportion of the crystalline state and the amorphous state in the material, so that the detection requirement of the UiO-66 material for levodopa is accurately matched, the detection range covering from ultratrace (10 nM) to high concentration (300 nM), the method has high sensitivity, meanwhile, excellent selectivity and stability are considered, the detection requirement of different scenes is met, and the method is suitable for wide application.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention provides a method for analyzing polypeptide or protein in a to-be-detected sample, which comprises the following steps of: separating by reversed-phase high-performance liquid chromatography, measuring the content of free amino acid before and after hydrolysis of the to-be-detected sample by a detector, determining the amino acid composition of the polypeptide or protein according to the difference value, and indirectly reflecting the content of polypeptide or protein impurities. The analysis method disclosed by the invention has the characteristics of simplicity in operation, strong specificity, high accuracy, good reproducibility and the like, and is successfully applied to analysis research and quality control of residual polypeptide impurities in raw material medicines of levodopa and lacosamide.

The present application relates to a kind of synthetic hydroxytyrosol multi-enzyme catalytic method.The synthetic hydroxytyrosol multi-enzyme catalytic method described in the present application includes first module reaction, second module reaction, third module reaction in turn;The first module reaction is that glycerol is synthesized pyruvic acid by catalysis, wherein the concentration of the glycerol is 1-5mM;The second module reaction is that pyruvic acid is condensed with catechol and ammonium chloride to be L-levodopa by catalysis;Wherein, the concentration of the catechol is 1-5mM, and the concentration of the catechol is greater than the concentration of the glycerol in the first module reaction;The third module reaction is that L-levodopa is synthesized hydroxytyrosol by catalysis.The synthetic hydroxytyrosol multi-enzyme catalytic method described in the present application, reaction 4 hours hydroxytyrosol molar conversion rate can reach 71.5%, compared with one-pot method has obvious advantage, in the same reaction time molar conversion rate is compared with one-pot method and increased nearly 6 times.

Provided herein are methods of treating a neurodegenerative disorder (e.g., Parkinson's disease) or symptoms thereof in a patient by administering to the patient doxycycline (or a pharmaceutically acceptable salt thereof), either alone or in combination with other therapeutic agents (e.g., levodopa).

The application provides a biomarker dopamine-3-O-sulfate (DA3S) for evaluating the risk of movement complications of Parkinson's disease patients. The application also provides a cerebrospinal fluid kit for evaluating the risk of movement complications of Parkinson's disease patients. The application is based on the concentration of DA3S in cerebrospinal fluid, and combines with clinical variables such as daily dose of levodopa (LEDD), disease duration, etc. to construct a joint prediction model, so as to realize early and quantitative individualized evaluation of the risk of movement complications of Parkinson's disease patients. The application also provides a plasma kit and a urine kit for evaluating the risk of movement complications of Parkinson's disease patients.

The invention provides adhesive type gastric retention administration hydrogel as well as a preparation method and application thereof, and belongs to the technical field of bioactive materials and drug delivery methods. The drug delivery hydrogel is prepared by taking levodopa modified hyaluronic acid as a skeleton structure, gluconic acid-delta-lactone as an acidity regulator and potassium sorbate as a preservative. The preparation method comprises the following steps: grafting levodopa onto hyaluronic acid, dialyzing, and freeze-drying to obtain levodopa modified hyaluronic acid; gluconic acid-delta-lactone, potassium sorbate and levodopa modified hyaluronic acid are mixed and dissolved in water, and after a reaction, the drug delivery hydrogel is obtained. Anthocyanin is loaded in administration hydrogel to prepare the gastric retention sustained-release medicinal preparation. The prepared drug delivery hydrogel has good oxidation resistance, biocompatibility, adhesion and drug sustained-release capacity, the hydrogel is endowed with sustained-release drug delivery capacity through the wet adhesion effect in the stomach wall environment, and the drug delivery hydrogel is widely applied to the fields of bioactive materials, drug delivery and food.

This invention relates to the field of biomedical materials technology, and more particularly to a flexible patch for treating nervous system diseases and its preparation method. It comprises: a flexible, breathable substrate composed of silk fibroin nanofibers, and drug-loaded nanoparticles loaded within the substrate; the drug-loaded nanoparticles are encapsulated with chitosan and contain levodopa and copper oxide nanoenzymes; the silk fibroin nanofibers are annealed with ethanol to form a controllable degradation structure, achieving self-adhesion and continuous drug release in a humid environment. This patch can simultaneously achieve stable delivery of dopamine and scavenging of reactive oxygen species, thus addressing the motor complications and neurooxidative damage caused by fluctuations in blood drug concentration in traditional Parkinson's disease treatment, achieving a dual synergistic treatment of symptom relief and neuroprotection.

The application discloses a levodopa plasma exposure reconstruction and pharmacokinetics inference method, system, device and storage medium based on multi-body fluid observation fusion and capillary blood anchor updating, the application breaks through the limitation of single body fluid observation through multi-body fluid observation fusion, can more comprehensively and accurately obtain the relevant information of levodopa in the body, provides more abundant and accurate data support for plasma exposure reconstruction, secondly, the capillary blood anchor updating mechanism can calibrate and update the related data in real time and dynamically, ensure the accuracy and timeliness of plasma exposure reconstruction, the combination of multi-body fluid observation fusion and capillary blood anchor updating mechanism innovation effectively improves the accuracy of levodopa plasma exposure reconstruction and the reliability of pharmacokinetics inference, can better assist medical personnel to understand the metabolism of levodopa in the patient's body, has important clinical application value and broad market prospect.

Disclosed herein are peptides compounds which are capable of forming collagen mimetic biomaterials. In some embodiments, the presently disclosed peptides may be stabilized by cation-pi interactions or by covalent interactions involving levodopa residues. In some embodiments, the present disclosure provides higher order structures formed from the peptides disclosed herein, including homotrimers, heterotrimers, and hydrogels.

The invention relates to a compound for targeted degradation of alpha-synuclein or a pharmaceutically acceptable salt thereof as well as a preparation method and application of the compound. The structural formula of the compound for targeted degradation of alpha-synuclein is shown as a general formula (I), the compound can degrade alpha-synuclein protein with a low dosage in vitro, levodopa is selected as a positive drug in an in-vivo experiment, it is proved that the compound can relieve dyskinesia caused by the Parkinson's disease, and the compound can be applied to drugs for relieving symptoms of the Parkinson's disease.

This invention discloses a method for synthesizing a green ratiometric fluorescent probe and its application in tetracycline detection, comprising the following steps: S1, dissolving levodopa in water to prepare a levodopa solution, adjusting the pH of the levodopa solution to alkaline, and stirring the reaction under open conditions at room temperature; S2, after the reaction is complete, filtering, dialyzing, and freeze-drying the reaction solution to obtain PDOPA solid powder; S3, dissolving the PDOPA solid powder in water to prepare a PDOPA solution, adding europium nitrate solution, mixing and stirring the reaction to obtain Eu. 3+ - PDOPA solution; S4, Add Eu 3+ -Dialysis of PDOPA solution yields Eu. 3+ -PDOPA ratiometric fluorescent probe solution. The Eu synthesized in this invention... 3+ -PDOPA ratiometric fluorescent probes have advantages such as simple preparation process, mild reaction conditions, good environmental compatibility, and strong fluorescence stability, and exhibit high selective recognition ability for tetracycline.

An aqueous pharmaceutical solution for the treatment of a central nervous system (CNS) disorder is provided, the solution comprising at least 5 mg / ml dissolved levodopa and a pH in the range of 3.0 to 8.5. The solution is provided by mixing: a) an aqueous stock solution comprising levodopa, the stock solution having a pH of less than 2.8 at 25°C, and b) an aqueous buffer solution for increasing the pH of the stock solution, the buffer solution having a pH of at least 4.0 at 25°C. The aqueous pharmaceutical solution is administered to a subject having a central nervous system (CNS) disorder shortly after mixing the aqueous stock solution and the aqueous buffer solution. Further, a kit for administering an aqueous pharmaceutical solution to a subject having a central nervous system (CNS) disorder is provided.

The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa.

This formulation can be applied to Parkinson's disease patients to improve the stability of levodopa (L-DOPA) in the body and its availability to the central nervous system. This formula can regulate the gut microbiota, strengthen the intestinal barrier function, reduce systemic inflammation and oxidative pressure, further improve motor and non-motor dysfunction, and delay or reduce the occurrence of side effects of long-term L-DOPA treatment, such as dysregulation. [Solution] The present invention discloses a probiotic cocktail medical food formulation that comprises at least one probiotic and can selectively combine one or more amino acids.

A fused ring compound of formula I, a pharmaceutical composition comprising same, a preparation method, a use for preventing and treating GPR6 receptor-mediated related diseases, such as movement disorders including Parkinson's disease, levodopa-induced dyskinesias, and Huntington's disease, drug addiction, eating disorders, cognitive disorders, schizophrenia, bipolar disorder, depression, etc., and a method.

This invention relates to a method for preparing a levodopa detection kit using chemiluminescent immunoassay. Due to the small molecular weight and poor immunogenicity of levodopa, and its presence of catechol in its structure, it is easily oxidized in neutral or alkaline environments. Therefore, when preparing the corresponding antibody, it is necessary to first select a suitable derivatization site and conjugate the derived hapten to a specific macromolecular carrier to prepare the complete antigen. This invention successfully prepared antibodies with good specificity and strong affinity through the design and modification of the hapten. This invention mainly relates to the design and synthesis of levodopa haptens, the preparation of complete levodopa antigens and anti-levodopa antibodies, and the methods, reagent composition, and components for determining levodopa concentration. The hapten design and synthesis of this invention mainly includes the design and chemical synthesis of levodopa derivatives. The levodopa derivative of this invention has the structure shown in formula (I): Formula (I).

The invention provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD6 or related gene and their use for producing L-DOPA from tyrosine and treating dopamine-responsive disorders, such as Parkinson's Disease. The invention also provides recombinant polynucleotides comprising a nucleic acid encoding a CYP76AD1 and / or CYP76AD6, a nucleic acid encoding a DOPA 4,5-dioxygenase (DOD) enzyme, such as Beta vulgaris DODA1, and, in some cases, a nucleic acid encoding betalain related glucosyltransferase, such as M. jalapa gene cyclo-DOPA 5-O-glucosyltransferase (cDOPA5GT), and their use for producing betalains. Finally, the invention provides chimeric polypeptides, expression vectors, cells, compositions, and organisms, including plants, and their uses in various methods of the invention.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a method for determining protein residues in levodobar synthesized by an enzyme method by utilizing high performance liquid chromatography. The method comprises the following steps: respectively detecting a blank solution, a reference solution and a test solution of levodopa by adopting a high performance liquid chromatography, recording chromatograms, and calculating the content of residual protein by peak area according to an external standard method, the residual protein being bovine serum albumin. The method has the technical advantages of high sensitivity, strong specificity and high accuracy, fills the blank of detection of protein residues in levodopa synthesized by an enzymic method in the prior art, provides key technical support for quality control of levodopa raw material medicines, and has important significance for guaranteeing medication safety of levodopa preparations.

The invention discloses a flexible wearable sensor for levodopa detection, which comprises a flexible substrate and a three-electrode system, and is characterized in that the three-electrode system unit is arranged on the flexible substrate; the three-electrode system comprises a working electrode, a counter electrode and a reference electrode. According to the flexible wearable sensor for levodopa detection disclosed by the embodiment of the invention, efficient real-time monitoring is realized through cooperation of an Au-MXene nano composite material and a microfluidic'self-refreshing 'system, MXene provides high conductivity and a large specific surface area, and Au nano particles enhance electrocatalytic activity, so that a levodopa oxidation reaction is remarkably accelerated; the bionic tree-shaped micro-channel is combined with a drain valve, sweat is driven without a pump through capillary force, it is ensured that fresh sweat flows through a sensing area preferentially, old sweat is discharged in order, the response time is shortened through the dual mechanism, minute-level concentration changes of levodopa in a human body can be accurately captured, and dynamic and real-time monitoring needed clinically is truly achieved.

A composition containing a mixture of oligomers or co-oligomers obtained by exposing an indolium-based monomer, optionally together with an additional monomer selected from dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a basic buffer. The composition may further contain a hydrophobic substance such as a drug or dietary supplement, stabilized by the oligomers above.

The present application relates to ophthalmic compositions comprising levodopa, an antioxidant, and an aqueous carrier. Disclosed are compositions comprising levodopa and an antioxidant for inhibiting the development or progression of visual disorders, including visual disorders associated with diabetic retinopathy or Parkinson's disease, as well as myopia.

The invention provides a method and a device for generating personalized levodopa prescription recommendation for Parkinson's disease, which are applied to the technical field of artificial intelligence, and the method comprises the following steps: carrying out virtual patient modeling based on patient data to obtain a virtual patient model, the virtual patient model is used for simulating pharmacokinetic behaviors of the levodopa preparation in the body of a patient and generating exercise symptom scores; inputting a preset medication behavior, the exercise symptom score and the patient data into the state transition model to obtain a prediction result of the symptom variation after the target time; and performing multi-stage reinforcement learning based on the patient data, the medication behavior and the prediction result of the symptom variation after the target time through the state transition model to obtain a personalized levodopa prescription strategy, the personalized levodopa prescription strategy being used for outputting levodopa prescription recommendation according to the input patient data. According to the invention, personalized and dynamic levodopa medication guidance can be provided for Parkinson's disease patients.

The invention discloses a method for preparing carbon isotope labeled levodopa through asymmetric synthesis. The method comprises the following steps: carrying out nucleophilic addition reaction on carbon isotope labeled CO2 and an aryl nucleophilic reagent to obtain carbon isotope labeled pepper acid; carrying out reduction and bromination reaction on piperic acid to synthesize a carbon isotope labeled aryl bromide fragment; the aryl bromide fragment and a chiral auxiliary Schiff base fragment are connected through an asymmetric alkylation reaction, and the carbon isotope labeled levodopa is obtained by removing an auxiliary and a protecting group from a connection product. According to the method, cheap and easily available raw materials are adopted, the cost is low, the yield is high, and the chiral center stereo enantioselectivity is high; according to the method, the L-DOPA can be accurately and stably labeled at the levodopa 3 site at a fixed point, the metabolic stability of the carbon isotope labeled L-DOPA is improved, the asymmetric synthesis of the carbon isotope labeled L-DOPA at the levodopa 3 site is completed for the first time, and a material support is provided for metabolism research related to the levodopa.

The invention discloses a preparation method of a peroxide-mediated high-ultraviolet-resistance melanin nano-material, which comprises the following steps: mixing a levodopa solution and a peroxide solution, adjusting the pH value of the solution to 5-6, and keeping stirring at room temperature to enable the levodopa to be subjected to oxidative polymerization reaction to obtain poly-levodopa nano-particles; the peroxide is a peroxide with a benzoyl group. The preparation method has the advantages of mild and controllable reaction process, low cost, environmental friendliness and the like; according to the melanin nano-particles prepared by the invention, benzoyl is grafted on the melanin nano-particles, and the melanin nano-particles are regular in structure and have excellent anti-ultraviolet performance.

The present disclosure provides compositions and methods for the treatment of levodopa-induced dyskinesia (LID) therewith. In particular, the present disclosure provides methods for treating LID by knocking down expression of the gene (GRIN2B) coding for the GluN2B subunit of N-methyl-d-aspartate receptors in indirect pathway spiny projection neurons (iSPNs) to attenuate the development and expression of LID without compromising the treatment of levodopa.